| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
||**
From the Departments of Pathology,
* Medicine,
and Radiation Oncology,
|| Brigham and Women’s Hospital, Boston, Massachusetts; the Departments of Medical Oncology
and Radiation Oncology,
** Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School,
Boston, Massachusetts; the Departments of Epidemiology and Biostatistics,
¶ Harvard School of Public Health, Boston, Massachusetts; and the Departments of Surgery and of Biochemistry and Molecular Biology,
University of Southern California Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, California
Assays to measure DNA methylation, which are important in epigenetic research and clinical diagnostics, typically rely on conversion of unmethylated cytosine to uracil by sodium bisulfite. However, no study has comprehensively evaluated the precision and performance characteristics of sodium bisulfite conversion and subsequent quantitative methylation assay. We developed quantitative real-time polymerase chain reaction (MethyLight) to measure percentage of methylated reference (PMR, ie, degree of methylation) for the MGMT, MLH1, and CDKN2A (p16) promoters. To measure the precision of bisulfite conversion, we bisulfite-treated seven different aliquots of DNA from each of four paraffin-embedded colon cancer samples. To assess run-to-run variation, we repeated MethyLight five times. Bisulfite-to-bisulfite coefficient of variation (CV) of PMR ranged from 0.10 to 0.38 (mean, 0.21), and run-to-run CV of PMR ranged from 0.046 to 0.60 (mean, 0.31). Interclass correlation coefficients were 0.74 to 0.84 for the three loci, indicating good reproducibility. DNA mixing study with methylated and unmethylated DNA showed good linearity of the assay. Of 272 colorectal cancers evaluated, most showed PMR either <1 or >10, and promoter methylation (PMR >4) was tightly associated with loss of respective protein expression (P < 10–16). In conclusion, sodium bisulfite conversion and quantitative MethyLight assays have good precision and linearity and can be effectively used for high-throughput DNA methylation analysis on paraffin-embedded tissue.
This article has been cited by other articles:
 |
|
 |
|
  A. R. Sepulveda, D. Jones, S. Ogino, W. Samowitz, M. L. Gulley, R. Edwards, V. Levenson, V. M. Pratt, B. Yang, K. Nafa, et al. CpG Methylation Analysis--Current Status of Clinical Assays and Potential Applications in Molecular Diagnostics: A Report of the Association for Molecular Pathology J. Mol. Diagn., July 1, 2009; 11(4): 266 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ogino, K. Nosho, N. Irahara, S. Kure, K. Shima, Y. Baba, S. Toyoda, L. Chen, E. L. Giovannucci, J. A. Meyerhardt, et al. A Cohort Study of Cyclin D1 Expression and Prognosis in 602 Colon Cancer Cases Clin. Cancer Res., July 1, 2009; 15(13): 4431 - 4438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ogino, K. Shima, K. Nosho, N. Irahara, Y. Baba, B. M. Wolpin, E. L. Giovannucci, J. A. Meyerhardt, and C. S. Fuchs A Cohort Study of p27 Localization in Colon Cancer, Body Mass Index, and Patient Survival Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1849 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nosho, K. Shima, N. Irahara, S. Kure, Y. Baba, G. J. Kirkner, L. Chen, S. Gokhale, A. Hazra, D. Spiegelman, et al. DNMT3B Expression Might Contribute to CpG Island Methylator Phenotype in Colorectal Cancer Clin. Cancer Res., June 1, 2009; 15(11): 3663 - 3671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Paya, C. Alenda, L. Perez-Carbonell, E. Rojas, J.-L. Soto, C. Guillen, A. Castillejo, V. M. Barbera, A. Carrato, A. Castells, et al. Utility of p16 Immunohistochemistry for the Identification of Lynch Syndrome Clin. Cancer Res., May 1, 2009; 15(9): 3156 - 3162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ogino, K. Nosho, G. J. Kirkner, K. Shima, N. Irahara, S. Kure, A. T. Chan, J. A. Engelman, P. Kraft, L. C. Cantley, et al. PIK3CA Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer J. Clin. Oncol., March 20, 2009; 27(9): 1477 - 1484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Liu, Y. Niu, Y. Yu, Y. Liu, and F. Zhang Increased {gamma}-tubulin expression and P16INK4A promoter methylation occur together in preinvasive lesions and carcinomas of the breast Ann. Onc., March 1, 2009; 20(3): 441 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Balic, M. Pichler, J. Strutz, E. Heitzer, C. Ausch, H. Samonigg, R. J. Cote, and N. Dandachi High Quality Assessment of DNA Methylation in Archival Tissues from Colorectal Cancer Patients Using Quantitative High-Resolution Melting Analysis J. Mol. Diagn., March 1, 2009; 11(2): 102 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Lee, B.-H. Kim, N.-Y. Cho, E. J. Yoo, M. Choi, S.-H. Shin, J.-J. Jang, K.-S. Suh, Y. S. Kim, and G. H. Kang Prognostic Implications of and Relationship Between CpG Island Hypermethylation and Repetitive DNA Hypomethylation in Hepatocellular Carcinoma Clin. Cancer Res., February 1, 2009; 15(3): 812 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ogino, K. Nosho, G. J Kirkner, T. Kawasaki, J. A Meyerhardt, M. Loda, E. L Giovannucci, and C. S Fuchs CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer Gut, January 1, 2009; 58(1): 90 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ogino, G. J. Kirkner, K. Nosho, N. Irahara, S. Kure, K. Shima, A. Hazra, A. T. Chan, R. Dehari, E. L. Giovannucci, et al. Cyclooxygenase-2 Expression Is an Independent Predictor of Poor Prognosis in Colon Cancer Clin. Cancer Res., December 15, 2008; 14(24): 8221 - 8227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ogino, K. Nosho, J. A. Meyerhardt, G. J. Kirkner, A. T. Chan, T. Kawasaki, E. L. Giovannucci, M. Loda, and C. S. Fuchs Cohort Study of Fatty Acid Synthase Expression and Patient Survival in Colon Cancer J. Clin. Oncol., December 10, 2008; 26(35): 5713 - 5720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ogino, K. Nosho, G. J. Kirkner, T. Kawasaki, A. T. Chan, E. S. Schernhammer, E. L. Giovannucci, and C. S. Fuchs A Cohort Study of Tumoral LINE-1 Hypomethylation and Prognosis in Colon Cancer J Natl Cancer Inst, December 3, 2008; 100(23): 1734 - 1738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. T. Viet and B. L. Schmidt Methylation Array Analysis of Preoperative and Postoperative Saliva DNA in Oral Cancer Patients Cancer Epidemiol. Biomarkers Prev., December 1, 2008; 17(12): 3603 - 3611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. C. Christensen, J. J. Godleski, C. J. Marsit, E. A. Houseman, C. Y. Lopez-Fagundo, J. L. Longacker, R. Bueno, D. J. Sugarbaker, H. H. Nelson, and K. T. Kelsey Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma Carcinogenesis, August 1, 2008; 29(8): 1555 - 1559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A.T. Rodriguez, A. S.L. Cheng, P. S. Yan, D. Potter, F. J. Agosto-Perez, C. L. Shapiro, and T. H.-M. Huang Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer Carcinogenesis, July 1, 2008; 29(7): 1459 - 1465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Iafrate and D. N. Louis "MGMT for pt mgmt": Is Methylguanine-DNA Methyltransferase Testing Ready for Patient Management? J. Mol. Diagn., July 1, 2008; 10(4): 308 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Vlassenbroeck, S. Califice, A.-C. Diserens, E. Migliavacca, J. Straub, I. Di Stefano, F. Moreau, M.-F. Hamou, I. Renard, M. Delorenzi, et al. Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma J. Mol. Diagn., July 1, 2008; 10(4): 332 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Kristensen, T. Mikeska, M. Krypuy, and A. Dobrovic Sensitive Melting Analysis after Real Time- Methylation Specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection Nucleic Acids Res., April 1, 2008; 36(7): e42 - e42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Feng, S. E. Hawes, J. E. Stern, L. Wiens, H. Lu, Z. M. Dong, C. D. Jordan, N. B. Kiviat, and H. Vesselle DNA Methylation in Tumor and Matched Normal Tissues from Non-Small Cell Lung Cancer Patients Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 645 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ogino and A. Goel Molecular Classification and Correlates in Colorectal Cancer J. Mol. Diagn., January 1, 2008; 10(1): 13 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bonanno, E. Shehi, D. Adlerstein, and G. M. Makrigiorgos MS-FLAG, a Novel Real-Time Signal Generation Method for Methylation-Specific PCR Clin. Chem., December 1, 2007; 53(12): 2119 - 2127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ogino, T. Kawasaki, G. J Kirkner, Y. Suemoto, J. A Meyerhardt, and C. S Fuchs Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer Gut, November 1, 2007; 56(11): 1564 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Coolen, A. L. Statham, M. Gardiner-Garden, and S. J. Clark Genomic profiling of CpG methylation and allelic specificity using quantitative high-throughput mass spectrometry: critical evaluation and improvements Nucleic Acids Res., September 25, 2007; 35(18): e119 - e119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Dejeux, V. Audard, C. Cavard, I. G. Gut, B. Terris, and J. Tost Rapid Identification of Promoter Hypermethylation in Hepatocellular Carcinoma by Pyrosequencing of Etiologically Homogeneous Sample Pools J. Mol. Diagn., September 1, 2007; 9(4): 510 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ogino, A. Hazra, G. J. Tranah, G. J. Kirkner, T. Kawasaki, K. Nosho, M. Ohnishi, Y. Suemoto, J. A. Meyerhardt, D. J. Hunter, et al. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer Carcinogenesis, September 1, 2007; 28(9): 1985 - 1990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ogino, T. Kawasaki, G. J. Kirkner, P. Kraft, M. Loda, and C. S. Fuchs Evaluation of Markers for CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer by a Large Population-Based Sample J. Mol. Diagn., July 1, 2007; 9(3): 305 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mikeska, C. Bock, O. El-Maarri, A. Hubner, D. Ehrentraut, J. Schramm, J. Felsberg, P. Kahl, R. Buttner, T. Pietsch, et al. Optimization of Quantitative MGMT Promoter Methylation Analysis Using Pyrosequencing and Combined Bisulfite Restriction Analysis J. Mol. Diagn., July 1, 2007; 9(3): 368 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nosho, H. Yamamoto, T. Takahashi, M. Mikami, H. Taniguchi, N. Miyamoto, Y. Adachi, Y. Arimura, F. Itoh, K. Imai, et al. Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers Carcinogenesis, June 1, 2007; 28(6): 1364 - 1370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ogino, T. Kawasaki, G. J. Kirkner, M. Loda, and C. S. Fuchs CpG Island Methylator Phenotype-Low (CIMP-Low) in Colorectal Cancer: Possible Associations with Male Sex and KRAS Mutations J. Mol. Diagn., November 1, 2006; 8(5): 582 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Ogino, M Cantor, T Kawasaki, M Brahmandam, G J Kirkner, D J Weisenberger, M Campan, P W Laird, M Loda, and C S Fuchs CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies Gut, July 1, 2006; 55(7): 1000 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. B. Coleman and A. G. Rivenbark Quantitative DNA Methylation Analysis: The Promise of High-Throughput Epigenomic Diagnostic Testing in Human Neoplastic Disease J. Mol. Diagn., May 1, 2006; 8(2): 152 - 156. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
